NeuronicLABs
NeuronicLABs is a Toronto-based pre-commercial medical device startup developing the QT100Dx, a fully automated, nanotechnology- and AI-driven RNA detection system for point-of-care molecular diagnostics, initially targeting SARS-CoV-2 saliva testing for clinicians and patients.
- Company typePrivate
- Founded2020
- HeadquartersNorth York, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeuronicLABs does
NeuronicLABs is a Toronto-based medical device company founded in February 2020 as a spinoff from Canadian engineering and technology design firm NeuronicWorks Inc. The company is developing the QT100Dx, a fully automated molecular diagnostic system intended to detect multiple RNA and protein targets at the point of care. The core technical innovation is quantum-scale, label-free RNA detection nanotechnology licensed from Ryerson University researchers, combined with automated sample preparation, AI-driven analytics, and a HIPAA-compliant cloud platform for real-time results access. The initial clinical focus is saliva-based detection of SARS-CoV-2 on a single testing cartridge, with the platform architecture intended to support broader infectious disease and biomarker testing.
The company operates in a pre-commercial stage: the QT100Dx is still under development and is explicitly not promoted as a medical device, with feasibility studies ongoing and Health Canada and FDA regulatory pathways not yet cleared. Go-to-market is partnership-led rather than direct sales; the company is actively soliciting strategic partners across R&D, engineering and design, advanced manufacturing, and business development. Intended revenue mechanics combine hardware sales (the QT100Dx device and consumable cartridges) with subscription/recurring revenue from cloud connectivity and analytics services, targeting healthcare providers, clinicians, and patients as primary users.
NeuronicLABs is led by CEO Simona Botos and CTO Milad Afshar and operates from a North York, Ontario headquarters that shares 40,000 sq. ft. of lab and fabrication facilities with NeuronicWorks, providing access to approximately 50 in-house engineers. The company is supported by a network of Canadian research and innovation partners including Ryerson University, NSERC, NRC, BiomedicalZone, OBIO, and ventureLAB. No funding rounds, institutional investment, or commercial revenue have been disclosed in available sources.
NeuronicLABs firmographics
Firmographics- Name
- NeuronicLABs
- Legal name
- NeuronicLABS Inc.
- Website
- https://neuroniclabs.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NeuronicLABs is a Toronto-based pre-commercial medical device startup developing the QT100Dx, a fully automated, nanotechnology- and AI-driven RNA detection system for point-of-care molecular diagnostics, initially targeting SARS-CoV-2 saliva testing for clinicians and patients.
- Ownership category
- akta.pro rank
NeuronicLABs industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where NeuronicLABs is headquartered
LocationHeadquarters
- HQ city
- North York
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
NeuronicLABs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- QT100Dx Diagnostic System: The company is developing a molecular diagnostic platform and point-of-care device for detecting infectious diseases including SARS-CoV-2. Revenue will likely come from hardware sales of the QT100Dx system and associated testing cartridges.
- Cloud Platform Services: HIPAA compliant cloud platform for real-time tracking, analysis, and results access, potentially generating recurring revenue from cloud connectivity and analytics services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NeuronicLABs product offering
Product offeringCore offering
NeuronicLABs is developing the QT100Dx, a fully automated molecular diagnostic system that detects multiple RNA and protein targets using quantum scale label-free technology combined with AI-driven analytics and automated sample preparation. The system is intended to enable decentralized, saliva-based infectious disease testing at the point of care, paired with a HIPAA-compliant cloud platform for real-time tracking and results delivery.
Product overview
NeuronicLABs offers a single unified product platform: the QT100Dx System, a molecular diagnostic platform currently under development. This fully automated system combines nanotechnology-based label-free detection with AI analytics to detect multiple RNA and protein biomarkers in decentralized point-of-care settings. The platform integrates automated sample preparation, cloud-based real-time tracking, and AI-driven analytics into a single testing cartridge designed for saliva-based testing.
Differentiator
Problem solved
Functional benefit
Products and services
- QT100Dx System A fully automated RNA detection system designed to accurately detect multiple RNA and protein targets at the point of care. It uses quantum scale technology for label-free detection of RNA and RNA-targeted molecules, with integrated AI analytics, automated sample preparation, and HIPAA-compliant cloud connectivity. Intended for clinicians and healthcare providers in decentralized settings performing saliva-based infectious disease testing. The system is still under development and is not yet promoted as a medical device.
Quantifiable outcome
- Portable, low-cost, high-throughput diagnostic device easy-to-operate by non-medical persons
- +1 more outcomes
Companies that use NeuronicLABs
Customer profileSegments2 records
Ideal customer profiles2 records
NeuronicLABs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature5 records
NeuronicLABs partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and supporting.
- Ryerson University (Prof. Bo Tan and Prof. Krishnan Venkat)coreNeuronicLABs partnered with Ryerson University to license their nanotechnology research and develop a molecular diagnostic platform for detecting infectious diseases. The partnership aims to commercialize the technology using NeuronicWorks' engineering expertise in AI and robotics.
- NeuronicWorks Inc.coreNeuronicLABs was spun off from NeuronicWorks, a leading engineering and technology design firm. NeuronicLABs benefits from shared facilities (40,000 sq. ft. of labs and fabrication) and access to 50 in-house engineers.
- NSERC (Natural Sciences and Engineering Research Council)supportingResearch funding and support partner for scientific research and development activities.
- NRC (National Research Council Canada)supportingFederal research organization providing support and resources for innovation and technology development.
- BiomedicalZonesupportingRyerson University's biomedical innovation hub supporting startups in the biomedical sector.
- OBIO (Ontario Bioscience Innovation Organization)supportingOntario-based organization supporting bioscience innovation and commercialization.
- ventureLABsupportingTechnology and innovation hub supporting technology ventures in Canada.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
NeuronicLABs competitors and assessment
Company assessmentMarket position
Strengths4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
NeuronicLABs social profiles
Digital presenceNeuronicLABs compliance and trust
Trust signalCompliance1 record
NeuronicLABs financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuronicLABs leadership team
Management profileNumber of profiles
Profiles2 records
NeuronicLABs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuronicLABs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuronicLABs
What does NeuronicLABs do?
NeuronicLABs is developing the QT100Dx, a fully automated molecular diagnostic system that detects multiple RNA and protein targets using quantum scale label-free technology combined with AI-driven analytics and automated sample preparation. The system is intended to enable decentralized, saliva-based infectious disease testing at the point of care, paired with a HIPAA-compliant cloud platform for real-time tracking and results delivery.
Is NeuronicLABs a public or private company?
NeuronicLABs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NeuronicLABs founded?
NeuronicLABs was founded in 2020. It employs 11 to 50 people.
Where is NeuronicLABs based?
NeuronicLABs is headquartered in North York, Canada, in the North America region.
How does NeuronicLABs make money?
Two revenue lines are on record. QT100Dx Diagnostic System is the primary driver. The others are cloud Platform Services.
Does NeuronicLABs have an API?
No public API is recorded for NeuronicLABs.
What industry is NeuronicLABs in?
NeuronicLABs's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 334516 and its SIC code is 3826.